These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Leonardi RA; Kransdorf EP; Simel DL; Wang A Circ Cardiovasc Interv; 2010 Apr; 3(2):97-104. PubMed ID: 20197511 [TBL] [Abstract][Full Text] [Related]
10. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Woo A; Williams WG; Choi R; Wigle ED; Rozenblyum E; Fedwick K; Siu S; Ralph-Edwards A; Rakowski H Circulation; 2005 Apr; 111(16):2033-41. PubMed ID: 15824202 [TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. ten Cate FJ; Soliman OI; Michels M; Theuns DA; de Jong PL; Geleijnse ML; Serruys PW Circ Heart Fail; 2010 May; 3(3):362-9. PubMed ID: 20332420 [TBL] [Abstract][Full Text] [Related]
13. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692 [TBL] [Abstract][Full Text] [Related]
14. Treatment modalities in hypertrophic obstructive cardiomyopathy: surgical myectomy versus percutaneous septal ablation. Vural AH; Tiryakioğlu O; Türk T; Ata Y; Ari H; Yalçinkaya S; Erkut B; Bozat T; Ozyazicioğlu A Heart Surg Forum; 2007; 10(6):493-7. PubMed ID: 18187386 [TBL] [Abstract][Full Text] [Related]
15. Selection of hypertrophic cardiomyopathy patients for myectomy or alcohol septal ablation. Lever HM Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():27-30. PubMed ID: 17162266 [TBL] [Abstract][Full Text] [Related]
16. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. van der Lee C; ten Cate FJ; Geleijnse ML; Kofflard MJ; Pedone C; van Herwerden LA; Biagini E; Vletter WB; Serruys PW Circulation; 2005 Jul; 112(4):482-8. PubMed ID: 16027255 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Minakata K; Dearani JA; Schaff HV; O'Leary PW; Ommen SR; Danielson GK Ann Thorac Surg; 2005 Sep; 80(3):851-6. PubMed ID: 16122442 [TBL] [Abstract][Full Text] [Related]
18. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Sorajja P; Binder J; Nishimura RA; Holmes DR; Rihal CS; Gersh BJ; Bresnahan JF; Ommen SR Catheter Cardiovasc Interv; 2013 Jan; 81(1):E58-67. PubMed ID: 22511295 [TBL] [Abstract][Full Text] [Related]
19. Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. Maron BJ; Yacoub M; Dearani JA Eur Heart J; 2011 May; 32(9):1055-8. PubMed ID: 21324934 [TBL] [Abstract][Full Text] [Related]
20. Golden jubilee of hypertrophic cardiomyopathy: is alcohol septal ablation the gold standard? Parakh N; Bhargava B Cardiovasc Revasc Med; 2009; 10(3):172-8. PubMed ID: 19595399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]